Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 61, Number 9, November 11, 2003
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lipp, A.
Right arrow Articles by Arnold, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipp, A.
Right arrow Articles by Arnold, G.
Related Collections
Right arrow Parkinson's disease/Parkinsonism
Right arrow Botulinum toxin
Right arrow Amyotrophic lateral sclerosis
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
NEUROLOGY 2003;61:1279-1281
© 2003 American Academy of Neurology
Brief Communications

A randomized trial of botulinum toxin A for treatment of drooling

A. Lipp, MD, T. Trottenberg, MD, T. Schink, A. Kupsch, MD and G. Arnold, MD

From the Department of Neurology, Medical Faculty of the Charité, Humboldt University, Berlin, Germany.

Address correspondence and reprint requests to Dr. Axel Lipp, Department of Neurology, Charite, Humboldt University of Berlin, Schumannstrasse 20/21, D-10117 Berlin, Germany.

The authors compared the efficacy of three different doses (18.75, 37.5, and 75 MU per parotid gland) of botulinum toxin A (BTX-A; Dysport, Ipsen Pharma, Germany) injections vs vehicle in patients with sialorrhea (n = 32) using a single-center, prospective, double-blind, placebo-controlled dose-finding study. The primary endpoint was achieved with 75 MU BTX-A without treatment-related adverse events, suggesting BTX-A is a safe and effective treatment for patients with sialorrhea.

Received February 3, 2003. Accepted in final form July 22, 2003.

Drs. Lipp and Trottenberg contributed equally to this article.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table ofContents for the November 11 issue to find the title link for this article.




This article has been cited by other articles:


Home page
 NeurologyHome page
M. Naumann, Y. So, C. E. Argoff, M. K. Childers, D. D. Dykstra, G. S. Gronseth, B. Jabbari, H. C. Kaufmann, B. Schurch, S. D. Silberstein, et al.
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, May 6, 2008; 70(19): 1707 - 1714.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. Benson and K. K Daugherty
Botulinum Toxin A in the Treatment of Sialorrhea
Ann. Pharmacother., January 1, 2007; 41(1): 79 - 85.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
S. Hassin-Baer, E. Scheuer, A. S. Buchman, I. Jacobson, and B. Ben-Zeev
Botulinum Toxin Injections for Children With Excessive Drooling
J Child Neurol, February 1, 2005; 20(2): 120 - 123.
[Abstract] [PDF]

Home page
 JWatch NeurologyHome page
Botulinum Toxin A Reduces Drooling in Neurodegenerative Diseases
Journal Watch Neurology, January 29, 2004; 2004(129): 6 - 6.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.